This trial has been completed.

Condition vascular disease
Sponsor Cedars-Sinai Medical Center
Collaborator Siemens Corporation, Corporate Technology
Start date May 2012
End date March 2015
Trial size 20 participants
Trial identifier NCT02065648, CSMC-2011-MR-02-01-NATIVE-Mos


The purpose of the study is to compare non-contrast abdominal MR Angiogram (MRA) syngo NATIVE sequence performed on a 3T Verio Siemens magnet to a standard contrast-enhanced MRA performed as part of routine clinical care in patients with normal renal function to determine if the non-contrast NATIVE sequence is a viable alternative to contrast enhanced MRA in patients with renal insufficiency. There are no interventions--this is an observational study.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.

Primary Outcomes

Effectiveness of non-contrast enhanced MRA sequence
time frame: 36 months

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: Over age 18 Signed informed consent Referred for standard of care MRA Exclusion Criteria: No contra-indications for MRI/MRA ie implants which could interfere with magnets Renal insufficiency which would preclude use of contrast-enhanced contrast for a standard of care MRA

Additional Information

Official title NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet
Principal investigator Rola Saouaf, MD
Description If the NATIVE sequence proves to be a viable alternative to contrast enhanced MRA it will provide imaging physicians with the diagnostic tool to assess vascular disease in patients with renal insufficiency without placing them at risk for additional co-morbidities.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Cedars-Sinai Medical Center.